US Edition
News from mammothtimes.com
We’ve assigned a rating of High factuality to mammothtimes.com. You can read more about how we’ve determined mammothtimes.com’s credibility and reliability as a news source here: https://ground.news/rating-system.
Media Bias Ratings
Average Bias Rating:
Center
Center
byMedia Bias/Fact CheckDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top mammothtimes.com News
Cyber Security · PennsylvaniaSAN FRANCISCO, Dec. 9, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating a data breach that led to unauthorized access to the sensitive information of 200,000 patients and employees of Tri-Century Eye Care P.C. ("Tri-Century"), a Pennsylvania-based eye…See the Story
PRIVACY ALERT: Tri-Century Eye Care Under Investigation for Data Breach of 200,000 Records
83% Center coverage: 18 sources
China · ChinaSAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major…See the Story
Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
83% Center coverage: 18 sources
